Isovanillin decreases the virulence regulated by the quorum sensing system of Pseudomonas aeruginosa

Junfeng Deng1, Yang Yuan2, Yi Wu1

  • 1Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, 610106, China.

Microbial Pathogenesis
|October 13, 2024
PubMed

Insights

Isovanillin effectively inhibits Pseudomonas aeruginosa virulence factors by disrupting quorum-sensing (QS) systems. This compound reduces pathogenicity and enhances antibiotic susceptibility in drug-resistant strains.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Computational Chemistry

Background:

  • Pseudomonas aeruginosa pathogenicity relies heavily on its quorum-sensing (QS) system.
  • Targeting the QS system offers a promising strategy to combat P. aeruginosa infections.

Purpose of the Study:

  • To identify novel anti-virulence compounds targeting P. aeruginosa QS.
  • To evaluate the efficacy of isovanillin in disrupting QS-regulated virulence factors.

Main Methods:

  • Virtual screening to identify potential QS inhibitors.
  • Experimental validation of isovanillin's inhibitory effects on virulence factors (protease, biofilm, pyocyanin).
  • RNA sequencing and qPCR to analyze gene expression changes.
  • Assessing antibiotic susceptibility and C. elegans infection models.

Main Results:

  • Isovanillin significantly inhibited QS-regulated virulence factors, including extracellular proteases, pyocyanin, and biofilm formation.
  • Sub-MIC doses of isovanillin down-regulated QS-activated genes at the transcriptional level.
  • Isovanillin increased the susceptibility of drug-resistant P. aeruginosa to multiple antibiotics.
  • Monotherapy with isovanillin reduced mortality in C. elegans infection models.

Conclusions:

  • Isovanillin exhibits significant anti-virulence activity against P. aeruginosa by targeting the QS system.
  • Isovanillin provides a structural basis for developing novel anti-virulence therapeutics against P. aeruginosa.